ClinicaliQ Trial Snapshot
- Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma — Recruiting • Phase I • Oncology • NCT05433142.
- Therapeutic Target: XmAb®819 is being tested as a potential treatment for advanced clear cell renal cell carcinoma (ccRCC), specifically in patients with relapsed or refractory disease who have limited treatment options after standard therapies.
- Patient Eligibility: The trial enrolls patients with advanced ccRCC that has progressed despite previous treatment; participants receive XmAb®819 via intravenous or subcutaneous administration, with the study designed to establish safety, tolerability, and optimal biological dosing.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Eligibility Snapshot
- : * Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by the local site investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. * Subjects who have relapsed and refractory ccRCC, pRCC, NSCLC, and CRC with evidence of disease progression on standard-of-care therapies * ECOG performance status of 0 or 1. * All subjects must have adequate tumor sample available (slides or archival FFPE blocks)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.